Beyond the Alpha and Omega: Redefining the Peroxisome Proliferator–Activated Receptor α Gut–Liver Axis in Intestinal Failure–Associated Liver Disease Authors: Chaowapong Jarasvaraparn, Brian J. Debosch, Abigail E. Russi Published: 2026 Short bowel syndrome (SBS) after massive intestinal resection disrupts physiological homeostasis throughout the body. Despite full recovery from the initial surgical changes, the liver remains at significant risk for intestinal failure–associated liver disease (IFALD).1 Initially thought to be exclusively driven by parenteral nutrition and stagnant bile flow, IFALD is now recognized as a complex manifestation of a disrupted gut–liver axis in patients with SBS.2 Although we know that improved enteral feedings are hepatoprotective and that there is intestinal adaptation in these patients, how best to restore and maintain homeostasis throughout the gut–liver axis remains a major knowledge gap. In this issue, Phelps et al dissect how enteral omega-3 and omega-6 fatty acids dictate both intestinal adaptation and hepatic injury within the gut–liver axis using a preclinical model of SBS.3 After SBS is induced with 75% short bowel resection (SBR), mice fed a diet enriched with omega-3 polyunsaturated fatty acids exhibited improved survival, weight recovery, metabolic efficiency, and hepatoprotection compared with those on omega-6 or balanced control diets. Importantly, the omega-3 diet also shifted the remnant ileum gene expression pattern to a more “proximalized” absorptive–gene signature. Bulk RNA sequencing and gene set variation analysis using the Zwick et al intestinal atlas demonstrate that enteral omega-3 polyunsaturated fatty acids drive the remnant ileum from a distal identity (Domains D/E) toward a proximal, jejunal-like identity (Domains A/B/C). This “proximalization” is characterized by the upregulation of intracellular lipid trafficking, (eg, enhanced expression of Fabp1, Apoc2, and Apoa5), and metabolic flux (eg, enhanced fatty acid beta–oxidation and oxidative phosphorylation pathways). Mechanistically, Phelps et al demonstrate robust omega-3 activation of the peroxisome proliferator–activated receptor α (Pparα) pathway with selectivity when compared with omega-6-induced activation of downstream Pparα targets. Surprisingly, an omega-3-enriched diet failed to promote survival in Pparα-deficient mice, yet pharmacologic Pparα activation was not sufficient to attenuate SBR-induced liver injury. The data indicate that Pparα activation is a critical adaptive survival pathway following SBR, yet omega-3 fatty acids may exert hepatoprotective effects independent of Pparα activation. The data prompt broader questions regarding what Pparα-independent hepatoprotective mechanisms are engaged upon omega-3 fatty acid feeding. Future advances in the field may thus: (1) define tissue-specificity of Pparα activation in promoting survival post SBR (eg, liver, enterocyte, or perhaps peripheral tissues); (2) elucidate modifiable, Pparα-independent pathways engaged by omega-3 fatty acid feeding; and (3) consider host-independent effects of enteral nutritional intervention in hepatoprotection during SBR, including modulating the gut microbiota and altering the bile acid pool. Deploying a tissue-specific Pparα-deficient model that dissociates the survival phenotype from hepatoprotection will be critical to defining these effects. This is especially important, given immune-suppressive interactions of Pparα that might confound conclusions regarding Pparα functions in survival and gut–liver axis function here. Understanding these hepatoprotective pathways may allow for synergistic therapeutic options in conjunction with already-existing United States Food and Drug Administration–approved Pparα agonist therapies in IFALD with potential implications to other inflammatory disorders of the gut-liver axis (eg, primary sclerosing cholangitis, primary biliary cholangitis). In light of this thought-provoking work by Phelps et al, we now have a clear path forward.